Cargando…
Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?
Protease-activated receptors (PARs) are a family of four GPCRs with a variety of cellular functions, yet the only advanced clinical endeavours to target these receptors for therapeutic gain to date relates to the impairment of platelet function for anti-thrombotic therapy. The only approved PAR anta...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888008/ https://www.ncbi.nlm.nih.gov/pubmed/31717963 http://dx.doi.org/10.3390/ijms20225629 |